JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes

"* Data record of patient will be reviewed for the following:~* Clinical features:~* Age~* Performance status~* Risk factors(smoking,stones or bilharziasis)~* Comorbidities~* Family history~* Pathological features:~* Histological subtype~* Grade~* Muscle invasion~* Carcinoma in situ~* Immunohistochemistry(IHC):~JAM3 expression by IHC~* TNM staging~* Number of chemotherapy cycles received~* Radical surgery or~* CCRT and type of concurrent~* Post treatment histological response~* . Follow-Up and Survival Analysis:~* During treatment: Monitoring for adverse events of chemotherapy and clinical response.~* After treatment: Imaging and clinical examination every 3 months for 2 years.~* Correlation of JAM3 expression with progression-free survival (PFS) and overall survival (OS).."